Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent

Written By Health Wildcatters
Health Wildcatters
Previous

Children’s Health Innovators Program Lifts Veil on Health Care Research and Breakthroughs
Next

What going public means for Lantern Pharma